Drug Profile
GSK 2879552
Alternative Names: GSK-2879552Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antineoplastics
- Mechanism of Action Co-repressor protein inhibitors; Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Myelodysplastic syndromes
- No development reported Acute myeloid leukaemia; Small cell lung cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Australia (PO, Capsule)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Canada (PO, Capsule)
- 28 Aug 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (PO, Capsule)